Glaukos

Yahoo Finance • 22 days ago

Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel

CARMEL, Ind. & LONDON, December 04, 2025--(BUSINESS WIRE)--Sudo Biosciences, ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appoi... Full story

Yahoo Finance • 2 months ago

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday

Key Points The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.10 stocks we like better than Glaukos › Glaukos(NYSE: GKOS), a biotech and phar... Full story

Yahoo Finance • 2 months ago

Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth

Earnings Call Insights: Glaukos Corporation (GKOS) Q3 2025 MANAGEMENT VIEW * CEO Thomas Burns began by highlighting "record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currenc... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Tesla and Netflix leads an earnings blitz, Samsung event, and delayed CPI

[View from Wall Street, New York City.] U.Ozel.Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 2 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif., October 14, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal... Full story

Yahoo Finance • 3 months ago

Glaukos gains as Goldman Sachs initiates at Buy on valuation

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Shares of Glaukos Corporation (NYSE:GKOS [https://seekingalpha.com/symbol/GKOS]) inched higher on Wednesday after Goldman Sachs initiated its coverage with a Buy recomme... Full story

Yahoo Finance • 3 months ago

3 Stocks That May Be Trading Below Estimated Fair Value

As the U.S. stock market navigates through a government shutdown and unexpected private-sector job losses, major indices like the Nasdaq and S&P 500 continue to show resilience, with recent gains bringing them near record highs. In this fl... Full story

Yahoo Finance • 3 months ago

3 Companies That May Be Priced Below Their Estimated Value

As the United States stock market navigates uncertainties such as potential government shutdowns and fluctuating commodity prices, major indices like the Dow Jones, Nasdaq, and S&P 500 have shown resilience with recent gains. In this envir... Full story

Yahoo Finance • 3 months ago

The Math Shows JHSC Can Go To $47

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Glaukos Corporation stands seventh among them. Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapi... Full story

Yahoo Finance • 4 months ago

Three Stocks That May Be Undervalued In August 2025

As of late August 2025, the U.S. stock market is experiencing a period of optimism, with major indices like the S&P 500 and Dow Jones Industrial Average reaching record highs. Amid this bullish environment, identifying undervalued stocks c... Full story

Yahoo Finance • 6 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., July 09, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the t... Full story

Yahoo Finance • 6 months ago

Glaukos receives EU certification for glaucoma surgery devices

ALISO VIEJO, Calif. - Glaukos Corporation (NYSE:GKOS), a $5.67 billion medical device company showing impressive revenue growth of nearly 24% over the last twelve months, has received European Union Medical Device Regulation certification... Full story

Yahoo Finance • 6 months ago

NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen S... Full story

Yahoo Finance • 6 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal dise... Full story

Yahoo Finance • 8 months ago

Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

Consolidated Net Sales: $106.7 million, up 25% on a reported basis or 26% on a constant currency basis year-over-year. Full Year 2025 Net Sales Guidance: Reaffirmed at $475 million to $485 million. US Glaucoma Franchise Net Sales: $59.1 mi... Full story

Yahoo Finance • 10 months ago

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

https://www.tipranks.com/news/the-fly/apple-unveils-iphone-16e-arista-reports-q4-beat-morning-buzz Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. Discover the Best Stocks and Maximize Your P... Full story

Yahoo Finance • last year

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 D... Full story

Yahoo Finance • last year

Should You Be Bullish on Glaukos Corporation (GKOS)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared t... Full story

Yahoo Finance • last year

Glaukos Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Glaukos (NYSE:GKOS) Second Quarter 2024 Results Key Financial Results Revenue: US$95.7m (up 19% from 2Q 2023). Net loss: US$53.9m (loss widened by 64% from 2Q 2023). US$1.06 loss per share (further deteriorated from US$0.68 loss in 2Q 20... Full story